 Kazia Therapeutics Ltd ASX:KZA NASDAQ:KZIA FRA:NV9 recently announced an agreement with Evotec SE FRA:EVT to in-license the global rights to EVT801, a novel inhibitor of vascular endothelial growth factor receptor 3 VEGFR3. Off the back of the deal, HC Wainwright Co analysts Sean Lee, Swayampakula Ramakanth, Arthur He, Sean Kang have maintained the companys BUY rating and 12-month price target of US17.00 per ADS. 